ADJUVANT CHEMOTHERAPY WITH CIS-DIAMMINODICHLOROPLATINUM-II AND 120-HOUR INFUSION 5-FLUOROURACIL IN STAGE-III AND STAGE-IV SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
ADJUVANT CHEMOTHERAPY WITH CIS-DIAMMINODICHLOROPLATINUM-II AND 120-HOUR INFUSION 5-FLUOROURACIL IN STAGE-III AND STAGE-IV SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
复制标题
DOI：
10.1002/1097-0142(19830415)51:8
复制
发表时间：
1983-01-01
期刊：
影响因子：
6.2
通讯作者：
ALSARRAF, M
中科院分区：
文献类型：
--
作者：
DECKER, DA;DRELICHMAN, A;ALSARRAF, M
进行了一项前瞻性研究，以研究35例局部晚期III期和IV期头颈部鳞状细胞癌患者在确定性手术和/或放射治疗前每3周联合大剂量推注CDDP [顺式二氯二氨铂II]和120小时连续输注5-FU [5-氟尿嘧啶]的3个疗程的有效性和毒性。患者（22例;在3个周期的化疗后，63%的患者达到CR [完全缓解]，11例（31%）达到PR [部分缓解]，客观缓解率为94%。毒性在临床上可接受。35例患者中有23例（66%）发生恶心和呕吐，没有任何患者因此停止治疗。白细胞减少13例（37%），可逆性氮质血症6例（17%）。化疗3个疗程后，13例患者行手术切除，12例患者行放射治疗。这35例患者中有10例在手术标本或放疗前活检中没有癌症的病理学证据。在达到完全客观缓解的患者中，仅2例复发;然而，中位随访时间较短。CDDP +5-FU 3个疗程是治疗晚期头颈部恶性肿瘤的一种安全、有效的辅助治疗方法。
A prospective study was carried out to investigate the effectiveness and toxicity of 3 courses of combination high-dose bolus CDDP [cis-diamminedichloroplatinum II] and 120-h continuous infusion 5-FU [5-fluorouracil] every 3 weeks prior to definitive surgery and/or radiation therapy in 35 patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck. Patients (22; 63%) achieved a CR [complete response] and 11 (31%) a PR [partial response] after 3 cycles of chemotherapy for an objective response rate of 94%. Toxicity was clinically acceptable. Nausea and vomiting occurred in 23 of 35 patients (66%) without any patients discontinuing therapy for this reason. Leukopenia occurred in 13 (37%) and reversible azotemia in 6 (17%). Following 3 courses of chemotherapy, 13 patients had surgical resection and 12 patients had radiation therapy. Ten of these 35 patients had no pathologic evidence of cancer in the surgical specimen or preradiation therapy biopsy. Only 2 patients of those achieving a complete objective response have relapsed; however, the median follow-up has been short. Three courses of CDDP and 5-FU is apparently a highly effective and safe adjuvant treatment in patients with advanced carcinoma of the head and neck.